Min Liao

Min Liao

Auto-generated profile, based on publicly available information

Min Liao

School of Pharmaceutical Sciences, Tsinghua University, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Blood
Verified
Journal Article
Closed access
PDF file
HHHanqing He
Hanqing He
PXPanglian Xu
Panglian Xu
XZXiaofei Zhang
Xiaofei Zhang
MLMin Liao
Min Liao
QDQiongye Dong
Qiongye Dong
JWJianwei Wang
Jianwei Wang
Hematopoietic stem cells (HSCs) aging correlates with an increasing risk of myelo-proliferative disease and immunosenescence. In this study, we show that aging-related inflammation promotes HSC aging through TNFα→ERK→ETS1→IL27Ra pathway. TNFα, a well-known biomarker of inflammation, increases during aging and induces the expression of IL27Ra on HSCs via ERK-ETS1 signaling. Deletion of IL27Ra rescues the functional decline and myeloid-bias of HSCs and also reverses the inhibitory effect of TNFα on HSCs. Aged IL27Ra-/- mice had a reduced proportion of myeloid-biased HSCs and did not display the biased myeloid differentiation that occurs in aged WT mice. IL27Ra+ HSCs exhibit impaired reconstitution capacity and myeloid-bias compared to IL27Ra- HSCs, and serve as a myeloid-recovery pool upon inflammatory insult. Inflammation-related genes were enriched in IL27Ra+ HSCs and this enrichment increases with aging. Our study demonstrates that age-induced IL27Ra signaling impairs HSCs and raises the possibility that interfering with IL27Ra signaling can counter the physiologically deleterious effect of aging on hematopoietic capacity.

18 October 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
MLMin Liao
Min Liao
QDQiongye Dong
Qiongye Dong
RCRuiqing Chen
Ruiqing Chen
LXLiqian Xu
Liqian Xu
YJYuxuan Jiang
Yuxuan Jiang
JWJianwei Wang
Jianwei Wang
DNA (cytosine-5)-methyltransferase 3A (DNMT3A) mutations occur in ~20% of de novo acute myeloid leukemia (AML) patients, and >50% of these mutations in AML samples are heterozygous missense alterations within the methyltransferase domain at residue R882. DNMT3A R882 mutations in AML patients promote resistance to anthracycline chemotherapy and drive relapse. In this study, we performed high-throughput screening and identified that oridonin, an ent-kaurene diterpenoid extracted from the Chinese herb Rabdosia rubescens, inhibits DNMT3A R882 mutant leukemic cells at a low-micromolar concentration (IC50 = 2.1 µM) by activating both RIPK1-Caspase-8-Caspase-3-mediated apoptosis and RIPK1-RIPK3-MLKL-mediated necroptosis. The inhibitory effect of oridonin against DNMT3A R882 mutant leukemia cells can also be observed in vivo. Furthermore, oridonin inhibits clonal hematopoiesis of hematopoietic stem cells (HSCs) with Dnmt3a R878H mutation comparing to normal HSCs by inducing apoptosis and necroptosis. Overall, oridonin is a potential and promising drug candidate or lead compound targeting DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia.